Showing results (181-190 of 204) with videos related to

Sort By:
Pageof 21
Journal of Clinical Pharmacology|August 26, 2018
FDA Public Meeting Report on "Drug Interactions With Hormonal Contraceptives: Public Health and Drug Development Implications"Mohammad Akbar, Erin Berry-Bibee, Diana L Blithe, et al.
Cytotherapy|March 12, 2023
Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myelomaSha Ma, Hujun Li, Dian Zhou, et al.
International Journal of Clinical and Experimental Medicine|December 3, 2015
Prospective cohort study to evaluate the efficacy of taxane plus platinum and CPT-11plus platinum regimes and to identify prognostic risk factors in cervical cancer patientsKecheng Huang, Xiong Li, Ru Yang, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|August 9, 2016
Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacyclineJimmy Flarakos, Yancy Du, Helen Gu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2021
Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid TumorsGiuseppe Curigliano, Hans Gelderblom, Nicolas Mach, et al.
Clinical and Experimental Medicine|September 4, 2024
Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myelomaRuixue Ma, Qi Zhang, Yang Liu, et al.
Science Translational Medicine|June 16, 2017
Donor pulmonary intravascular nonclassical monocytes recruit recipient neutrophils and mediate primary lung allograft dysfunctionZhikun Zheng, Stephen Chiu, Mahzad Akbarpour, et al.
Journal for Immunotherapy of Cancer|March 18, 2020
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumorsAung Naing, Justin F Gainor, Hans Gelderblom, et al.
Blood Advances|September 29, 2021
Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myelomaYing Wang, Chunrui Li, Jieyun Xia, et al.
Scientific Reports|June 22, 2016
Optimal pathological response indicated better long-term outcome among patients with stage IB2 to IIB cervical cancer submitted to neoadjuvant chemotherapyKecheng Huang, Haiying Sun, Zhilan Chen, et al.
Pageof 21